Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „sections“
Suchtreffer
Begriffe & Kennungen
Reyataz · 4.3 · Patients with moderate to severe hepatic insufficiency (see sections 4.2 and 4.4).
Eintrag öffnenReyataz · 4.3 · REYATAZ is contraindicated in patients with severe hepatic insufficiency (see sections 4.2, 4.4 and 5.2). REYA
Eintrag öffnenRimmyrah · 4.5 · For the adjunctive use of laser photocoagulation and ranibizumab in DME and BRVO, see sections 4.2 and 5.1.
Eintrag öffnenRimmyrah · 4.5 · For the adjunctive use of laser photocoagulation and ranibizumab in DME and BRVO, see sections 4.2 and 5.1.
Eintrag öffnenRistaben · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see sections 4.4 a
Eintrag öffnenRistfor · 4.3 · - hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.
Eintrag öffnenRotaTeq · 4.3 · Infants who have known or suspected immunodeficiency (see sections 4.4 and 4.8).
Eintrag öffnenRystiggo · 4.5 · 5 live-attenuated or live vaccines is not recommended during treatment with rozanolixizumab (see sections 4.4
Eintrag öffnenRückenmarkverletzungen
Eintrag öffnenSchnittentbindung
Eintrag öffnenSchnittentbindung, wiederholte
Eintrag öffnenSitagliptin / Metformin hydrochloride Mylan · 4.3 · - hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.
Eintrag öffnenSitagliptin / Metformin hydrochloride Sun · 4.3 · - hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.
Eintrag öffnenSitagliptin Accord · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see sections 4.4 a
Eintrag öffnenSynovektomie
Eintrag öffnenTaxotere · 4.3 · Patients with severe liver impairment (see sections 4.2 and 4.4).
Eintrag öffnenTaxotere · 4.3 · Patients with severe liver impairment (see sections 4.2 and 4.4).
Eintrag öffnenTaxotere · 4.3 · Patients with severe liver impairment (see sections 4.2 and 4.4).
Eintrag öffnenTaxotere · 4.8 · The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mi
Eintrag öffnenTaxotere · 4.8 · The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mi
Eintrag öffnen